A phase 1 single ascending dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SRP-1005 in subjects with Huntington’s Disease (INSIGHTT)

Principal Investigator

Dr Richard Armstrong

Contact us

Email: dendron@ouh.nhs.uk

IRAS number

1013732